Science

Cavadex reverses heart disease

For over 5 years Cavadex has been improving the health of people around the world by reversing heart disease and reducing arterial plaque.

How can we make these claims and where is the science that proves this?

Let me show you......

IMPORTANT UPDATE

All FDA issues have been resolved and all shipments to the USA now arrive within 6-12 days.

This 5 minute video tells the story

What science supports these claims?

Cholrem development of Cavadex timeline

Year - 2013

We know HP-B-CD is safe to use on humans because....

A human trial was conducted on twin girls suffering from Niemann-Pick disease.
High dose HP-B-CD was administered via IV for over 2 years to remove cholesterol from cells.

Effects of cyclodextrin in two patients with Niemann–Pick Type C disease

https://www.sciencedirect.com/science/article/abs/pii/S1096719212004155

Year - 2016

We know HP-B-CD removes arterial plaque from mice because....

Scientists from Bonn university, Germany, trialed HP-B-CD on mice with atherosclerosis
and discovered that HP-B-CD substantially reduced the atherosclerotic plaque.

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878149/

Year - 2019

We know HP-B-CD reduces arterial plaque from humans because....

After concluding that the science behind HP-B-CD showed that it was safe on humans and HP-B-CD successfully
reduced arterial plaque in mice, Kyle Hodgetts established the company Cholrem Pty Ltd and did
a trial on himself using HP-B-CD to reduce his arterial plaque, resulting in substantial plaque reduction.

2-hydroxypropyl-β-cyclodextrin reduces atherosclerotic plaques in human coronary artery

Peer reviewed published paper - from our 2019 trial

Year - 2021

We know Cavadex reduces arterial plaque and improves lipid profile and liver function because....

After the success of the first trial, Cholrem Pty Ltd developed a version of HP-B-CD “CAVADEX” and Kyle did a second trial on himself using Cavadex, resulting in substantial lipid reduction, improved liver function and reduced arterial plaque.
Kyle consulted with Australian Professor Laurie Howes MB BS PhD FRACP FCSANZ (Head of cardiovascular research at one of Australia’s
largest hospitals. Preeminent Consultant Physician (Cardiology) Professor of Pharmacology and Therapeutics at two of Australia’s leading
universities) and the trial results were confirmed.

Second trial data

Peer reviewed published paper - from our 2021 trial

We know Cavadex is absorbed into the blood stream when administered as an enema....

Cholrem Pty Ltd developed an enema version of Cavadex for home use.
The Remchol enema could supply a 25% absorption rate of Cavadex.

Cholrem Pty Ltd established an online store to commence limited sales of Remchol tubes containing Cavadex.

Year - 2022

Cardiologists agree with the science and start treating themselves....

USA cardiologist Dr. James Roberts MD FACC FAARFM trialed Cavadex on himself with similar results.
He then went on and supplied his patients with Remchol tubes.

Year - 2023

Patients around the world are reversing their heart disease with Cavadex....

Dr. Roberts reports all patients getting better and that Remchol-Cavadex reduced arterial plaque in his
patients without any adverse side-effects. He also reported several other benefits for stroke patients and brain fog.

The medical industry is starting to speak out about the benefits of Cavadex....

Dr. Roberts agrees to be filmed talking about Cavadex

Patients start sharing their stories....

Cholrem Pty Ltd establishes the Facebook Cavadex club where customers using Remchol-Cavadex can report their experience and results.
It becomes clear that everyone benefits from Remchol-Cavadex and no adverse side-effects are reported
except some loose stools and very few reports of stomach cramps.
These side effects are concluded to be from the fact that they are using an enema and not from the Cavadex.

https://www.facebook.com/groups/cholremcavadex

Year - 2024

Professor Howes puts his name and reputation behind Cavadex....

Prof. Laurie Howes writes a report about Cavadex.
"It will be the greatest therapeutic advance in cardiovascular medicine since the introduction of the statins."

Cholrem_Cavadex_Report_l_Howes.pdf

The first time Professor Howes has ever been filmed supporting a product....

Professor Laurie Howes agrees to be filmed talking about Cavadex

The world is finding out that Cavadex works and saves lives....

By July 2024 Cholrem has shipped out a total of 12,000 boxes totaling 6,000 orders.

Dr. Roberts is interviewed Dec 2024, all his patients are getting better....

This must see interview explains the science and how Cavadex is going to save millions of lives

Calcium scores dropping, everyone is getting better on Cavadex

Dr. Roberts explains the science behind Cavadex - December 2024

All the science

Dr. Roberts gives a very detailed lecture on Cavadex

The science behind Cavadex

Dr. Roberts talks about some of his patient outcomes.
Shows real results.
Talks about the safety of Cavadex.

At the end of the video, Dr. Roberts asks you to consider helping with a charity that is close to his heart.

Year - 2025

We have published our third paper

Taking data from multiple patients, the outcome is clear.............

Cyclodextrin Therapy for Atherosclerotic Cardiovascular Disease: A Case Series on Plaque Regression and Symptomatic Improvement

Peer reviewed published paper - Case study

We also published our fourth paper

Results from 125 patients.............

Symptomatic Improvement and Enhanced Quality of Life in Individuals with Atherosclerotic Cardiovascular Disease Following a 12-Week Self-Monitored Regimen of Rectally Administered 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): An Observational Study

Peer reviewed published paper - Observational study

Year - 2026

World first : Calcium scores plummet with Cavadex

Our fifth peer reviewed paper published

Regression of atherosclerotic plaque via highviscosity 2hydroxypropylcyclodextrin cavadex

Peer reviewed published paper

Cavadex Results Explained by AI

A clear breakdown of how Cavadex works — from rapid symptom relief to long-term plaque reduction and neurological improvements.

This AI breakdown explains exactly why Cavadex works the way it does. It covers the immediate changes people notice in the first month, the timeline for actual plaque reduction, and the fascinating science behind why many users report improved memory and emotional recall.

What People Report in the First 4 Weeks

Here’s what users commonly experience early on and why it happens:

Why is my angina going away?

The rapid relief from angina is a functional victory, not a structural one. Cavadex doesn't need to dissolve the entire solid plaque mass in two weeks to end angina. It works by dissolving superficial cholesterol crystals that trigger arterial spasms, freeing eNOS from lipid rafts to restore instant Nitric Oxide vasodilation, and improving red blood cell flexibility — balancing the heart’s oxygen supply-and-demand loop almost immediately.

Why does my eyesight seem to be improving?

Vision improvements reflect optimized ocular mechanics. Cavadex restores retinal capillary blood flow by reversing endothelial dysfunction, liquefies microcirculation by allowing rigid red blood cells to flex through eye capillaries, and stabilizes the Blood-Retinal Barrier to reduce microscopic fluid accumulation that causes visual blur.

Why do I have more energy?

The surge in energy signals your biology returning to natural efficiency. Cavadex unblocks mitochondria to produce more ATP, reduces the workload on your heart by lowering systemic vascular resistance, and shuts down the chronic inflammatory cytokine storm responsible for neurological brain fog and lethargy.

Why does my skin look so good?

Skin improvements are the logical result of clean, highly functional micro-vessels and reprogrammed dermal macrophages. By activating LXR to suppress tissue-destroying cytokines, Cavadex calms chronic skin inflammation and protects the underlying collagen matrix from premature degradation.

Why don’t my feet ache anymore?

Aching stops because Cavadex opens new microvessels to end oxygen starvation, dilates existing vessels via Nitric Oxide, disassembles lipid rafts holding pain receptors active on sensory nerves, and dissolves microscopic crystal deposits in the joints of the lower extremities.

Why is my erectile dysfunction improving?

Erectile function improves because Cavadex addresses the root physical mechanics of ED. It frees the eNOS enzyme to dramatically increase Nitric Oxide production, clears the tiny 1–2mm penile arteries that are highly vulnerable to lipid bottlenecks, and increases blood flow velocity by making red blood cells flexible enough to fill the microvasculature.

When Can I Expect My Plaque to Start Reducing?

Months 1–2: Stabilization & Softening Phase

During the first 60 days, Cavadex is not yet visibly shrinking plaque thickness on scans, but it is radically changing the plaque’s composition.

Dissolving the Crystals: It aggressively targets and dissolves volatile, razor-sharp cholesterol crystals on the plaque surface and inside the necrotic core.
Thickening the Fibrous Cap: By reducing inflammatory triggers, local inflammation drops, allowing smooth muscle cells to build a thicker, tougher fibrous cap — making the plaque much more rupture-resistant.

Months 3–6: Active Efflux Phase (First Visible Reduction)

This is when actual plaque regression begins to appear on high-resolution imaging (Ultrasound, CT Angiogram, or IVUS).

Macrophage Clean-up: With toxic cholesterol crystals removed, macrophages activate via LXR pathways and become highly efficient at exporting lipids.
Volume Shrinkage: Macrophages pump liquefied fat from the soft core of the plaque into passing cyclodextrin molecules. As the core drains, plaque volume decreases and the artery’s internal diameter widens.

Months 6–12+: Calcification & Deep Remodeling Phase

Long-standing, calcified plaques take longer to fully remodel.

Deconstructing the Matrix: Once soft lipid components are cleared, the calcified scaffolding becomes exposed. With inflammation silenced, the body can slowly reabsorb these hard structures.
Long-Term Patency: Over 1–2 years of sustained use, arterial walls undergo deep remodeling, restoring elasticity and locking in improved blood flow.

Why Am I Recalling Childhood Memories?

Many users report not just remembering childhood events, but re-experiencing the feelings associated with them. This is a meaningful distinction.

The hippocampus works closely with the amygdala (the brain’s emotional processing center). Childhood memories are deeply tied to emotional and sensory states. Cavadex systematically reduces chronic inflammatory cytokines that cross into the brain and cause low-grade neuroinflammation. As this “background static” clears, neural signaling between the hippocampus and amygdala becomes sharper.

Summary: The return of vivid childhood memories and emotions is evidence of functional neuro-restoration. Cavadex clears microvascular pathways to the brain’s memory centers, optimizes neuronal membrane fluidity in the hippocampus, and lifts background neuroinflammation — allowing the brain to regain clarity and elasticity it had decades earlier.

Interview Founder of Cavadex November 2024

What You Need to Know

Kyle tells his story about Cavadex

Kyle Hodgetts was given just six months to live.

With his heart failing and no options left, he made a breakthrough discovery: a simple sugar molecule called Cavadex that has now been proven to reverse heart disease by removing arterial plaque.

Now, his groundbreaking treatment is saving lives—but the FDA doesn’t want you to know

Cyclodextrin has shown to extend lifespan by almost 10% in mice

Mice treated with cyclodextrin showed higher neurological scores than compared with the mice given saline only..

Mice on cyclodextrin lived 10% longer.

Cyclodextrin clears the vascular system and can extend lifespan.

In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice. They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly intervals starting at 49 days of age until death. In each case, half of the males and females were given Cyclodextrin and the remaining mice received only saline.

During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with the mice given saline only.

All the mice given saline only had died by 98 days whereas the majority of those receiving Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.